Jul 06, 2013, 02.50 PM | Source: CNBC-TV18
Gautam Sinha Roy of Motilal Oswal Securities expects 7-8 percent upside in Lupin in near term.
Gautam Sinha Roy (more)
VP-Equity Strategy & Product, Motilal Oswal | Capital Expertise: Equity - Fundamental
"So, lot of positive tailwinds are there for Lupin. That is the main reason why we continue to like this stock at this point of time," he added.
Speaking from the sidelines of the India Pharmaceu
Astellas submitted a new drug application (NDA) wi
In a BSE filing, Lupin said "its Japanese subsidia
Lupin's Japanese subsidiary Kyowa Pharmaceutical I
Axis Direct recommended hold rating on Lupin with